Charming Medical (MCTA) Q4 2026 earnings summary

Executive summary

• Revenue for FY2026 was $4.81M, down 22.7% from FY2025, mainly due to lower customer spending and the closure of a key service center.

• Net loss for FY2026 was $22,648, compared to net income of $1.2M in FY2025, reflecting decreased sales and increased professional expenses.

• The company completed its IPO in October 2025, raising $6.5M in net proceeds, but trading was suspended in November 2025 due to SEC concerns over potential market manipulation.

• Ms. Kit Wong surrendered all Class B shares in July 2026, consolidating voting rights to one vote per share.

Financial highlights

• FY2026 revenue: $4.81M (down 22.7% YoY); FY2025: $6.22M (up 3.4% YoY); FY2024: $6.02M.

• FY2026 net loss: $22,648; FY2025 net income: $1.2M; FY2024 net income: $822K.

• FY2026 operating expenses: $4.84M, flat YoY; professional fees rose to $782K (up 352%).

• Cash and cash equivalents at March 31, 2026: $4.7M, up from $817K in 2025.

• Working capital surplus at March 31, 2026: $3.84M, versus a deficit of $1.58M in 2025.

Outlook and guidance

• Management expects current cash, operating cash flow, and IPO proceeds to meet working capital needs for the next 12 months.

• No dividends are planned in the foreseeable future; earnings will be retained for operations and growth.

• The company is focused on expanding international presence, investing in R&D, and diversifying product offerings.